Analyst consensus rating
Amgen Analyst Rating: Buy
AMGN is rated Buy by 29 analysts with a $388.48 target. As of 2026-08-27.
Direct answer
Amgen's consensus rating is Buy.
29 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $388.48.
Forecast evidence checked August 27, 2026.
Get free Amgen email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $440.34
- Average price target
- $388.48
- High price target
- $457.00
- Low price target
- $230.00
- Low target gap
- -47.8%
- Target upside
- -11.8%
- High target gap
- +3.8%
- Target range width
- 51.6%
- Consensus rating
- Buy
- Analysts
- 29
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Amgen?
Amgen has a verified Buy consensus. The same dataset has an average price target of $388.48.
How far are Amgen's low and high targets from the recorded price?
The low target implies -47.8%, while the high target implies +3.8%.
How many analysts are included in Amgen's consensus?
The verified consensus includes 29 analysts.
How is Amgen's target upside or downside calculated?
The average target of $388.48 is divided by the recorded price of $440.34, then one is subtracted to produce -11.8%. This does not guarantee a future return.
When was Amgen's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.